EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye

Hulya Maras Genc, Fulya Kurekci, Gulten Ozturk, Ayfer Sakarya Gunes iD, Sema Saltik, Mehmet Akif Kilic iD, Gokce Cirdi, Olcay Unver, Mustafa Komur, Ismail Hakki Akbeyaz, Yılmaz Zindar, Leman Tekin Orgun und 8 weitere

Muscle & Nerve · 2026-06 · 73 (6) · 966-975

DOI: 10.1002/mus.70191 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Muscle & Nerve, online erschienen am 27.02.2026. Verfasst von Hulya Maras Genc und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Neurology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Oligonucleotides, Survival of Motor Neuron 2 Protein, Recombinant Fusion Proteins. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Data comparing nusinersen monotherapy with combination therapy using nusinersen and onasemnogene abeparvovec (OA) in spinal muscular atrophy (SMA) type 1 patients are limited. This study aimed to compare the clinical outcomes of nusinersen monotherapy versus combination therapy (nusinersen and OA) in SMA type 1 patients with two SMN2 copies.

Methods

This retrospective multicenter study included 82 patients divided into nusinersen monotherapy ( n = 42) and combination therapy ( n = 40) groups. Outcomes included motor milestones, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP‐INTEND) scores, respiratory and nutritional status, and survival. Patients were stratified by age at treatment initiation (≤ 3, 3–6, and > 6 months). An age‐matched subgroup analysis was performed.

Results

Age at treatment initiation, total administered nusinersen doses, and follow‐up duration were comparable between groups. All deaths ( n = 8) occurred in the monotherapy group among patients who initiated treatment after 3 months of age ( p = 0.005). There was no significant difference between groups in the age at achieving unsupported sitting. In the age‐matched subgroup analysis ( n = 44, 22 per group), no significant differences were found between monotherapy and combination therapy in terms of motor function, CHOP‐INTEND progression, respiratory and feeding status. Earlier treatment was associated with better feeding outcomes (OR: 0.740, p = 0.024). Pre‐treatment respiratory and feeding status were also predictive of corresponding outcomes.

Discussion

Early treatment is the main determinant of outcomes, while combination therapy shows no clear advantage over monotherapy. Larger prospective studies are needed to clarify the role and timing of combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal Muscular Atrophies of ChildhoodOligonucleotidesSurvival of Motor Neuron 2 ProteinRecombinant Fusion ProteinsHumansFemaleMaleInfantRetrospective StudiesTreatment OutcomeDrug Therapy, CombinationChild, PreschoolGene Therapy Agents

Stichwörter der Autor:innen

combination therapynusinersenonasemnogene abeparvovecspinal muscular atrophy type 1two SMN2 copies

Substanzen

nusinersenOligonucleotidesonasemnogene abeparvovecSurvival of Motor Neuron 2 ProteinRecombinant Fusion ProteinsSMN2 protein, human

Autor:innen und Institutionen

  • Division of Pediatric Neurology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
  • Division of Pediatric Neurology, Department of Pediatrics, Sanliurfa Training and Research Hospital, Sanliurfa, Türkiye.
  • Division of Pediatric Neurology, Department of Pediatrics, Marmara University School of Medicine, Istanbul, Türkiye.
  • Division of Pediatric Neurology, Department of Pediatrics, Kocaeli University Faculty of Medicine, Istanbul, Türkiye.
  • Division of Pediatric Neurology, Department of Pediatrics, Istanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine, Istanbul, Türkiye.
  • Division of Pediatric Neurology, Department of Pediatrics, Mersin University Faculty of Medicine, Istanbul, Türkiye.

ORCID-Profile: Ayfer Sakarya Gunes, Mehmet Akif Kilic

Zitieren

APA

Genc, H. M., Kurekci, F., Ozturk, G., Gunes, A. S., Saltik, S., Kilic, M. A., Cirdi, G., Unver, O., Komur, M., Akbeyaz, I. H., Zindar, Y., Orgun, L. T., Kayar, C. D., Guler, S., Caglar, E., Sengec, E., Yildiz, E. P., Kara, B., Turkdogan, D., & Marmara Region SMA Study Group (2026). Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye. Muscle & Nerve, 73(6), 966-975. https://doi.org/10.1002/mus.70191

Vancouver

Genc HM, Kurekci F, Ozturk G, Gunes AS, Saltik S, Kilic MA, et al. Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye. Muscle & Nerve. 2026;73(6):966-975. doi:10.1002/mus.70191

BibTeX
@article{Genc2026,
  author = {Genc, Hulya Maras and Kurekci, Fulya and Ozturk, Gulten and Gunes, Ayfer Sakarya and Saltik, Sema and Kilic, Mehmet Akif and Cirdi, Gokce and Unver, Olcay and Komur, Mustafa and Akbeyaz, Ismail Hakki and Zindar, Yılmaz and Orgun, Leman Tekin and Kayar, Cisem Duman and Guler, Serhat and Caglar, Ezgi and Sengec, Esma and Yildiz, Edibe Pembegul and Kara, Bulent and Turkdogan, Dilsad and Marmara Region SMA Study Group, Marmara Region SMA Study Group},
  title = {Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye},
  journal = {Muscle & Nerve},
  year = {2026},
  volume = {73},
  number = {6},
  pages = {966--975},
  doi = {10.1002/mus.70191}
}
Kostenlos starten →